PDCD1 and neoplasm: Disease progression of ~16 months in patients after pembrolizumab (anti–PD-1) treatment of refractory/relapsed cHL, though achieving an excellent response rate, indicated a non-durable long-term memory for anti-tumor immunologic response [31,106].